DDInter1233 DDInter824
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic barrier against resistance mutations of the virus. In cell cultures, the emergence of amino acid substitutions at NS3 resistance-associated positions A156 or D/Q168 in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility to glecaprevir [FDA Label]. The combinations of amino acid substitutions at NS3 position Y65H and D/Q168 also results in greater reductions in glecaprevir susceptibility, and NS3 Q80R in genotype 3a patients also leads to glecaprevir resistance [FDA Label]. Glecaprevir is available as an oral combination therapy with under the brand name Mavyret. This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis . Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both . Hepatitis C viral infection often leads to decreased liver function and subsequent liver failure, causing a significantly negative impact on the patients' quality of life. The ultimate goal of the combination treatment is to achieve sustained virologic response (SVR) and cure the patients from the infection. In clinical trials, this combination therapy achieved SVR12 rate, or undetectable Hepatitis C for twelve or more weeks after the end of treatment, of ≥93% across genotypes 1a, 2a, 3a, 4, 5 and 6 [FDA Label].
Mitotane {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Griseofulvin
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Mitotane {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Glecaprevir
Mitotane {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Bosutinib
Bosutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Glecaprevir
Mitotane {u} (Compound) upregulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Simvastatin
Simvastatin {u} may lead to a major life threatening interaction when taken with {v} Glecaprevir
Mitotane {u} (Compound) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is bound by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may lead to a major life threatening interaction when taken with {v} Glecaprevir
Mitotane {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Dexamethasone
Dexamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Mitotane {u} (Compound) downregulates {v} (Gene) DNMT3A
DNMT3A {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Pazopanib {u} may lead to a major life threatening interaction when taken with {v} Glecaprevir
Mitotane {u} (Compound) resembles {v} (Compound) Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glecaprevir
Mitotane (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Griseofulvin (Compound) and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Mitotane (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may lead to a major life threatening interaction when taken with Glecaprevir
Mitotane (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Bosutinib (Compound) and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is bound by Simvastatin (Compound) and HMGCR (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may lead to a major life threatening interaction when taken with Glecaprevir
Mitotane (Compound) upregulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Simvastatin (Compound) and Simvastatin may lead to a major life threatening interaction when taken with Glecaprevir
Mitotane (Compound) downregulates HMGCR (Gene) and HMGCR (Gene) is bound by Rosuvastatin (Compound) and Rosuvastatin may lead to a major life threatening interaction when taken with Glecaprevir
Mitotane (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Mitotane (Compound) downregulates DNMT3A (Gene) and DNMT3A (Gene) is downregulated by Pazopanib (Compound) and Pazopanib may lead to a major life threatening interaction when taken with Glecaprevir
Mitotane (Compound) resembles Chlorpheniramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir